Article Text

MG-133 Development and launch of an expanded pan-ethnic carrier screening panel
  1. Ashley H Birch1,
  2. Guiqing Cai1,
  3. Xiaoqiang Cai1,
  4. Anastasia Fedick1,
  5. Lama Elkhoury1,
  6. Janelle McCarthy1,
  7. Maria Delio1,
  8. Jinglan Zhang2,
  9. Ruth Kornreich1,
  10. Lisa Edelmann1
  1. 1Mount Sinai Genetic Testing Laboratory, Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  2. 2Baylor Miraca Genetic Laboratories, Baylor College of Medicine, Houston, TX, USA


Background Prenatal carrier screening has traditionally focused on well-defined ethnic groups with an increased chance of being a carrier for specific genetic diseases. However, many people are of mixed ethnicity or cannot accurately identify their full ethnic.

With the ability to test for hundreds of diseases at one time, expanded carrier screening panels are an attractive option.

Objectives To build a comprehensive pan-ethnic carrier screening panel with a rapid turnaround time (TAT).

Design/method Following literature review, internal research, and physician input, a panel of 281 autosomal recessive and X-linked diseases were selected. Next generation sequencing (NGS) was performed using Agilent’s SureSelect QXT target enrichment approach followed by Illumina HiSeq 2500 Rapid Run mode sequencing. Additional methodologies include MLPA, Asuragen CGG repeat analysis/Southern blotting, and Sequenom/Luminex genotyping assays to assay variants not amenable to NGS. Variant confirmation is performed simultaneously by genotyping, or subsequently by Sanger sequencing. Over 3,700 recurrent pathogenic variants with a well-established relationship to disease phenotype are guaranteed to be sequenced at a depth of > 20X.

Results 524 validation samples were tested, including positive controls with various mutation types, and both prenatal and postnatal samples covering a variety of specimen types. A minimum average coverage of 240X was achieved, with > 20X coverage of 99% of bases.

Conclusions This panel can be customizable to order, including a high-frequency panel of 10 diseases, a Comprehensive Jewish panel of 96 diseases, and the full 281 gene panel. Automation can handle thousands of samples per month. TAT currently averages 8–10 days.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.